DE60031396D1 - Zubereitung zur behandlung von einer neurologischen erkrankung - Google Patents
Zubereitung zur behandlung von einer neurologischen erkrankungInfo
- Publication number
- DE60031396D1 DE60031396D1 DE60031396T DE60031396T DE60031396D1 DE 60031396 D1 DE60031396 D1 DE 60031396D1 DE 60031396 T DE60031396 T DE 60031396T DE 60031396 T DE60031396 T DE 60031396T DE 60031396 D1 DE60031396 D1 DE 60031396D1
- Authority
- DE
- Germany
- Prior art keywords
- preparation
- treatment
- neurological disease
- rar22
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1783—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- High Energy & Nuclear Physics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9907461 | 1999-03-31 | ||
| GBGB9907461.9A GB9907461D0 (en) | 1999-03-31 | 1999-03-31 | Neurite regeneration |
| PCT/GB2000/001211 WO2000057900A2 (en) | 1999-03-31 | 2000-03-30 | Factor for regulation of neurite growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60031396D1 true DE60031396D1 (de) | 2006-11-30 |
| DE60031396T2 DE60031396T2 (de) | 2007-08-30 |
Family
ID=10850746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60031396T Expired - Fee Related DE60031396T2 (de) | 1999-03-31 | 2000-03-30 | Zubereitung zur behandlung einer neurologischen erkrankung |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20070054961A1 (de) |
| EP (2) | EP1180039B1 (de) |
| JP (1) | JP2002540164A (de) |
| KR (1) | KR20010104401A (de) |
| CN (1) | CN100350970C (de) |
| AT (1) | ATE342728T1 (de) |
| AU (1) | AU770394B2 (de) |
| CA (1) | CA2369009A1 (de) |
| DE (1) | DE60031396T2 (de) |
| GB (2) | GB9907461D0 (de) |
| WO (1) | WO2000057900A2 (de) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1268835B1 (de) * | 2000-03-30 | 2008-01-16 | Oxford Biomedica (UK) Limited | Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen |
| GB0103998D0 (en) * | 2001-02-19 | 2001-04-04 | King S College London | Method |
| US7490472B2 (en) | 2003-02-11 | 2009-02-17 | Statoil Asa | Efficient combined cycle power plant with CO2 capture and a combustor arrangement with separate flows |
| EP2931899A1 (de) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Funktionale genomik unter verwendung von crispr-cas systemen, zusammensetzungen, verfahren, knockout-bibliotheken und anwendungen davon |
| SG11201504523UA (en) | 2012-12-12 | 2015-07-30 | Broad Inst Inc | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| JP6738729B2 (ja) | 2013-06-17 | 2020-08-12 | ザ・ブロード・インスティテュート・インコーポレイテッド | 分裂終了細胞の疾患および障害をターゲティングおよびモデリングするための系、方法および組成物の送達、エンジニアリングおよび最適化 |
| CA2915795C (en) | 2013-06-17 | 2021-07-13 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components |
| KR20240172759A (ko) | 2013-06-17 | 2024-12-10 | 더 브로드 인스티튜트, 인코퍼레이티드 | 간의 표적화 및 치료를 위한 ＣＲＩＳＰＲＣａｓ 시스템, 벡터 및 조성물의 전달 및 용도 |
| EP3653229A1 (de) | 2013-12-12 | 2020-05-20 | The Broad Institute, Inc. | Abgabe, verwendung und therapeutische anwendungen der crispr-cas-systeme und zusammensetzungen zur genomeditierung |
| SG10201804975PA (en) | 2013-12-12 | 2018-07-30 | Broad Inst Inc | Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders |
| BR112016013520A2 (pt) | 2013-12-12 | 2017-10-03 | Broad Inst Inc | Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos |
| WO2015089486A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
| EP4219699A1 (de) | 2013-12-12 | 2023-08-02 | The Broad Institute, Inc. | Konstruktion von systemen, verfahren und optimierten führungszusammensetzungen mit neuen architekturen zur sequenzmanipulation |
| DK3180426T3 (da) | 2014-08-17 | 2020-03-30 | Broad Inst Inc | Genomredigering ved anvendelse af cas9-nickaser |
| WO2016049163A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
| WO2016049258A2 (en) | 2014-09-25 | 2016-03-31 | The Broad Institute Inc. | Functional screening with optimized functional crispr-cas systems |
| WO2016094880A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs) |
| EP3889260A1 (de) | 2014-12-12 | 2021-10-06 | The Broad Institute, Inc. | Geschützte guide-rnas (pgrnas) |
| WO2016094872A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Dead guides for crispr transcription factors |
| WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
| US9994559B2 (en) | 2014-12-17 | 2018-06-12 | King's College London | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists |
| EP3234192B1 (de) | 2014-12-19 | 2021-07-14 | The Broad Institute, Inc. | Unbeeinflusste identifizierung von doppelstrangbrüchen und genomischer umordnung durch genomweite einsatzerfassungssequenzierung |
| WO2016106236A1 (en) | 2014-12-23 | 2016-06-30 | The Broad Institute Inc. | Rna-targeting system |
| WO2016106244A1 (en) | 2014-12-24 | 2016-06-30 | The Broad Institute Inc. | Crispr having or associated with destabilization domains |
| EP3822291A1 (de) | 2015-06-10 | 2021-05-19 | The Broad Institute Inc. | Antikörper, verbindungen und tests zur identifizierung und behandlung von kachexie oder präkachexie |
| CA3012607A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Crispr enzymes and systems |
| CA3012631A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| WO2016205745A2 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Cell sorting |
| KR102575342B1 (ko) | 2015-06-18 | 2023-09-05 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적외 효과를 감소시키는 crispr 효소 돌연변이 |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| WO2017031370A1 (en) | 2015-08-18 | 2017-02-23 | The Broad Institute, Inc. | Methods and compositions for altering function and structure of chromatin loops and/or domains |
| US12241053B2 (en) | 2015-10-09 | 2025-03-04 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| KR102761827B1 (ko) | 2015-10-22 | 2025-02-03 | 더 브로드 인스티튜트, 인코퍼레이티드 | 타입 vi-b crispr 효소 및 시스템 |
| WO2017074788A1 (en) | 2015-10-27 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for targeting cancer-specific sequence variations |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| WO2017106657A1 (en) | 2015-12-18 | 2017-06-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| WO2017189308A1 (en) | 2016-04-19 | 2017-11-02 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| US20210155911A1 (en) | 2016-04-19 | 2021-05-27 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| AU2017253107B2 (en) | 2016-04-19 | 2023-07-20 | Massachusetts Institute Of Technology | CPF1 complexes with reduced indel activity |
| WO2017219027A1 (en) | 2016-06-17 | 2017-12-21 | The Broad Institute Inc. | Type vi crispr orthologs and systems |
| GB201610867D0 (en) | 2016-06-22 | 2016-08-03 | King S College London | Crystalline forms of a therapeutic compound and processes for their preparation |
| WO2018005873A1 (en) | 2016-06-29 | 2018-01-04 | The Broad Institute Inc. | Crispr-cas systems having destabilization domain |
| US11352647B2 (en) | 2016-08-17 | 2022-06-07 | The Broad Institute, Inc. | Crispr enzymes and systems |
| CN110312799A (zh) | 2016-08-17 | 2019-10-08 | 博德研究所 | 新型crispr酶和系统 |
| WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
| US20200016202A1 (en) | 2016-10-07 | 2020-01-16 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| WO2018138385A1 (en) | 2017-01-30 | 2018-08-02 | Kws Saat Se | Repair template linkage to endonucleases for genome engineering |
| AU2018234825B2 (en) | 2017-03-15 | 2020-12-17 | Massachusetts Institute Of Technology | Novel CAS13B orthologues CRISPR enzymes and systems |
| EP3610009A1 (de) | 2017-04-12 | 2020-02-19 | The Broad Institute, Inc. | Neuartige typ-vi-crispr-orthologe und systeme |
| WO2018191750A2 (en) | 2017-04-14 | 2018-10-18 | The Broad Institute Inc. | Novel delivery of large payloads |
| US11591601B2 (en) | 2017-05-05 | 2023-02-28 | The Broad Institute, Inc. | Methods for identification and modification of lncRNA associated with target genotypes and phenotypes |
| KR102338449B1 (ko) | 2017-09-21 | 2021-12-10 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물 |
| EP3692152A4 (de) | 2017-10-04 | 2021-12-01 | The Broad Institute, Inc. | Verfahren und zusammensetzungen zur veränderung der funktion und struktur von chromatinschleifen und/oder -domänen |
| WO2019135816A2 (en) | 2017-10-23 | 2019-07-11 | The Broad Institute, Inc. | Novel nucleic acid modifiers |
| US11547614B2 (en) | 2017-10-31 | 2023-01-10 | The Broad Institute, Inc. | Methods and compositions for studying cell evolution |
| US12221720B2 (en) | 2017-11-13 | 2025-02-11 | The Broad Institute, Inc. | Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells |
| US12018080B2 (en) | 2017-11-13 | 2024-06-25 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway |
| US10968257B2 (en) | 2018-04-03 | 2021-04-06 | The Broad Institute, Inc. | Target recognition motifs and uses thereof |
| WO2020033601A1 (en) | 2018-08-07 | 2020-02-13 | The Broad Institute, Inc. | Novel cas12b enzymes and systems |
| WO2020041380A1 (en) | 2018-08-20 | 2020-02-27 | The Broad Institute, Inc. | Methods and compositions for optochemical control of crispr-cas9 |
| US11384344B2 (en) | 2018-12-17 | 2022-07-12 | The Broad Institute, Inc. | CRISPR-associated transposase systems and methods of use thereof |
| US12215382B2 (en) | 2019-03-01 | 2025-02-04 | The General Hospital Corporation | Liver protective MARC variants and uses thereof |
| WO2020191102A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
| WO2020236972A2 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
| GB201907647D0 (en) | 2019-05-30 | 2019-07-17 | King S College London | Therapeutic methods |
| AU2023250649A1 (en) | 2022-04-04 | 2024-11-14 | The Regents Of The University Of California | Genetic complementation compositions and methods |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| JP2608540B2 (ja) | 1982-05-19 | 1997-05-07 | ギスト ブロカデス ナ−ムロ−ゼ フエンノ−トチヤツプ | クルイベロミセス種のためのクローニング系 |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| EP0134048B2 (de) | 1983-07-06 | 1996-08-14 | Gist-Brocades N.V. | Molekulare Klonierung und Expression in industriellen Mikroorganismen |
| US4885249A (en) | 1984-12-05 | 1989-12-05 | Allelix, Inc. | Aspergillus niger transformation system |
| AU606033B2 (en) | 1985-04-15 | 1991-01-31 | Dsm Ip Assets B.V. | Promotors of filamentous fungi and use thereof |
| NO872932L (no) | 1986-07-18 | 1988-01-19 | Gist Brocades Nv | Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika. |
| IL85093A0 (en) * | 1987-01-16 | 1988-06-30 | Us Health | Pharmaceutical compositions containing retinoids for the treatment of psychotic illnesses |
| US4808630A (en) * | 1987-01-16 | 1989-02-28 | United States Of America | Method of treating psychotic illnesses |
| NZ225597A (en) | 1987-07-28 | 1991-08-27 | Gist Brocades Nv | Use of kluyveromyces in the production of chymosin, tpa, hsa and other proteins |
| KR100225087B1 (ko) | 1990-03-23 | 1999-10-15 | 한스 발터라벤 | 피타아제의 식물내 발현 |
| CA2211142A1 (en) * | 1995-01-23 | 1996-08-01 | Ligand Pharmaceuticals Incorporated | Human retinoid x receptor - gamma (hrxr-gamma) |
| IT1276459B1 (it) * | 1995-06-30 | 1997-10-31 | Khodor Ammar | Composizioni cosmetiche con proprieta' antimicotiche, efficaci contro la psoriasi e la caduta dei capelli e metodo cosmetico per la |
| FR2739557B1 (fr) * | 1995-10-09 | 1997-11-14 | Cird Galderma | Utilisation d'un ligand agoniste specifique rar-gamma |
| US5965606A (en) * | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
| AU6897498A (en) | 1997-04-25 | 1998-11-24 | American Home Products Corporation | Human neuronal cell line |
| CA2307826A1 (en) * | 1997-10-27 | 1999-05-06 | Creative Biomolecules, Inc. | Enhancement of morphogen activity |
-
1999
- 1999-03-31 GB GBGB9907461.9A patent/GB9907461D0/en not_active Ceased
-
2000
- 2000-03-30 AT AT00918991T patent/ATE342728T1/de not_active IP Right Cessation
- 2000-03-30 JP JP2000607650A patent/JP2002540164A/ja active Pending
- 2000-03-30 WO PCT/GB2000/001211 patent/WO2000057900A2/en active IP Right Grant
- 2000-03-30 EP EP00918991A patent/EP1180039B1/de not_active Expired - Lifetime
- 2000-03-30 GB GB0123381A patent/GB2365772A/en not_active Withdrawn
- 2000-03-30 CN CNB008080887A patent/CN100350970C/zh not_active Expired - Fee Related
- 2000-03-30 KR KR1020017012263A patent/KR20010104401A/ko not_active Application Discontinuation
- 2000-03-30 AU AU39755/00A patent/AU770394B2/en not_active Ceased
- 2000-03-30 CA CA002369009A patent/CA2369009A1/en not_active Abandoned
- 2000-03-30 EP EP06076367A patent/EP1762243A1/de not_active Withdrawn
- 2000-03-30 DE DE60031396T patent/DE60031396T2/de not_active Expired - Fee Related
-
2006
- 2006-09-25 US US11/526,458 patent/US20070054961A1/en not_active Abandoned
-
2009
- 2009-09-30 US US12/570,659 patent/US20100317109A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1180039B1 (de) | 2006-10-18 |
| GB9907461D0 (en) | 1999-05-26 |
| CA2369009A1 (en) | 2000-10-05 |
| EP1762243A1 (de) | 2007-03-14 |
| US20070054961A1 (en) | 2007-03-08 |
| AU770394B2 (en) | 2004-02-19 |
| WO2000057900A2 (en) | 2000-10-05 |
| JP2002540164A (ja) | 2002-11-26 |
| DE60031396T2 (de) | 2007-08-30 |
| KR20010104401A (ko) | 2001-11-26 |
| ATE342728T1 (de) | 2006-11-15 |
| WO2000057900A3 (en) | 2001-02-15 |
| GB2365772A (en) | 2002-02-27 |
| CN100350970C (zh) | 2007-11-28 |
| EP1180039A2 (de) | 2002-02-20 |
| US20100317109A1 (en) | 2010-12-16 |
| CN1355706A (zh) | 2002-06-26 |
| GB0123381D0 (en) | 2001-11-21 |
| AU3975500A (en) | 2000-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60031396D1 (de) | Zubereitung zur behandlung von einer neurologischen erkrankung | |
| DE69829921D1 (de) | Vorrichtung zur Behandlung von Körpergewebe | |
| ATE472325T1 (de) | Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen | |
| DE69903543D1 (de) | Formulierungen zur behandlung von magen-speiseröhren reflux | |
| DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
| DE60019556D1 (de) | 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit | |
| ATE271038T1 (de) | 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen | |
| DE60019555D1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
| ATE417602T1 (de) | Mittel zur behandlung von erkrankungen der speiseröhre | |
| ATE447947T1 (de) | Pharmazeutische zubereitungen zur behandlung von insulinresitenz | |
| DE60022916D1 (de) | Reboxetin zur Behandlung von peripheren Neuropathien | |
| DE60114808D1 (de) | Oberflächenbehandlung von medizinischer vorrichtung | |
| DE60023128D1 (de) | Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen | |
| DE69936335D1 (de) | Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen | |
| DE60028863D1 (de) | Elektrochirurgisches Handstück zur Behandlung von Gewebe | |
| ATA76995A (de) | Stabiles präparat zur behandlung von blutgerinnungsstörungen | |
| ATE292134T1 (de) | Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien | |
| DE60029033D1 (de) | Verfahren zur Behandlung von Tissuepapier | |
| DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
| DE69824576D1 (de) | Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen | |
| DE50013843D1 (de) | Arzneimittel zur behandlung von darmerkrankungen | |
| DE69910202D1 (de) | EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden | |
| DE69420229D1 (de) | Pharmazeutische Zusammensetzung zur Behandlung von AIDS | |
| DE69822297D1 (de) | Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten | |
| DE60001255D1 (de) | Zusammensetzung zur Behandlung von Polyesterfaser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |